Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y<sub>12</sub>Receptor Antagonist Activity
Y. Niitsu(Daiichi-Sankyo (Japan)), Fumitoshi Asai(Azabu University), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Joseph A. Jakubowski(Indiana Biosciences Research Institute)
Cited by 236
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617